Talecris IPO:
Another Bioscience Milestone for NC
The exit strategy of Talecris is also its entrance—into a new kind of public life.
Talecris’ Initial Public Offering (IPO) of stock is the kind of transition celebrated by the North Carolina Biotechnology Center and the statewide bioscience community it serves.
It is America’s second-biggest of 2009 —and the only biotech IPO. The company's IPO raised $950 million.
Since Talecris was founded in Research Triangle Park in 2005, it has become one of the state’s largest and fastest-growing biotechnology companies. It employs 2,300 North Carolinians at facilities in RTP, Clayton and Winston-Salem. More than 4,500 work for Talecris globally.
Its new owners—the shareholders—are scattered throughout the United States and beyond.